| Document |
Document Title |
|
WO/2023/222144A1 |
An SGLT2 (sodium glucose transport protein 2) inhibitor having a novel molecular structure, a preparation method therefor, and a use thereof. The SGLT2 inhibitor is a thioglycoside gliflozin analogue; same is designed using C-glycoside a...
|
|
WO/2023/220174A1 |
This application relates to salts of ascarosides, which can provide various benefits over corresponding ascarosides. For example, certain ascaroside salts can provide beneficial nutrients to a plant to which or near which the salt is app...
|
|
WO/2023/216732A1 |
Provided is a chemical synthesis method for a helicobacter pylori core lipopolysaccharide oligosaccharide antigen carbohydrate chain, belonging to the field of carbohydrate chemistry. Eight monosaccharide building blocks are prepared by ...
|
|
WO/2023/213035A1 |
Disclosed is a method for preparing an aryl carbon glycoside compound including a gliflozin drug, belonging to the technical field of pharmaceutical chemistry. According to the present invention, a sulfinate glycosyl donor represented by...
|
|
WO/2023/214629A1 |
The present invention relates to a composition comprising a pentagalloyl glucose derivative and a phenol compound as active ingredients. The composition according to an aspect not only can be used for anticancer and antidiabetic purposes...
|
|
WO/2023/213034A1 |
Disclosed are a sulfinate glycosyl donor, a method for preparing same, and use thereof, belonging to the technical field of pharmaceutical chemistry. The present invention particularly provides a sulfinate glycosyl donor represented by f...
|
|
WO/2023/215306A1 |
Provided herein are improved processes for the preparation of a carbohydrate targeting moiety and its intermediates (I).
|
|
WO/2023/210233A1 |
The present invention addresses the problem of providing a technique for effectively exerting the activity of a polynucleotide in the brain. The problem is solved by a compound represented by general formula (1) [In the formula, Ms repre...
|
|
WO/2023/211280A1 |
Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof: The substituents are as defined herein. Also provided are pharmaceutical compositions comprising the compounds, as well as ...
|
|
WO/2023/205206A1 |
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods fo...
|
|
WO/2023/202034A1 |
The present invention relates to the technical field of biology, and relates to an oligosaccharide fluorescent marker, a preparation method therefor, and use thereof. The preparation method of the present invention comprises the followin...
|
|
WO/2023/198682A1 |
Compound of the general formula (Ia), (Ib) and (Ic) R50 and R60 are different form each other and are selected from the group consisting of -R70, -ZR70, -Z-OH, -Z-NH2, -Z-SH, -Z-OC(O)R70, -OC(O)R70, - COOH and its corresponding salts, -C...
|
|
WO/2023/196636A1 |
This application relates to methods of inhibiting the growth of microbes in and/or on plant-based products by treating the plant-based products with a composition including one or more ascarosides.
|
|
WO/2023/194941A1 |
Methods of preparing N-acetyllactosamine derivatives for use in the preparation 3'-O-glycosyl- and 2',3'-di-O-glycosyl-N-acetyllactosamine derivatives are described. The methods avoid the use of column chromatography and allow for the pr...
|
|
WO/2023/185505A1 |
A compound of a heparin trisaccharide structure and a preparation method therefor. The compound of the heparin trisaccharide structure has a single optical activity, and the core structure is Glc(1→4)IdoA(1→4)GlcNS. The compound can ...
|
|
WO/2023/191531A1 |
The present invention relates to a composition for preventing, ameliorating, or treating inflammatory diseases, allergic diseases, or sepsis. As a composition that inhibits the expression or activity of pro-inflammatory cytokines IL-8 or...
|
|
WO/2023/191513A1 |
The present invention relates to a composition comprising an imidazoline derivative and a sugar as active ingredients. According to the composition and a micelle according to an aspect, the solubility of the imidazoline derivative can be...
|
|
WO/2023/175140A1 |
The present invention relates to new carbohydrate derivatives with activity as mimetics of blood group A and B antigens. The present invention also relates to a method for preparing said carbohydrate derivatives and to a glycoconjugate c...
|
|
WO/2023/177970A1 |
A method for making highly soluble steviol glycoside compositions. The method can provide steviol glycoside solutions having a high concentration of dissolved steviol glycosides, and which exhibit long-term resistance to precipitation. V...
|
|
WO/2023/175536A1 |
Provided herein are compounds that contain one or more lipophilic moieties and can be used to prepare one or more lipophilic monomers. Also provided herein are lipophilic monomers that can be conjugated to one or more positions on at lea...
|
|
WO/2023/168520A1 |
The present disclosure relates generally to compounds, compositions, antibodies, and methods for raising and utilising an immune response in a subject, comprising administering to a subject an isolated or synthesised Pseudomonas aerugino...
|
|
WO/2023/166488A1 |
Provided herein are aminoglycoside compounds, such as compounds of Formula (I) and Formula (III), and pharmaceutically acceptable salts thereof, useful as therapeutic and/or prophylactic agents. The compounds may be useful in treating a ...
|
|
WO/2023/165381A1 |
Provided are an acyl-based statin compound with lipase inhibitory activity, a preparation method therefor, and use thereof in controlling body weight and treating obesity.
|
|
WO/2023/162946A1 |
The purpose of the present invention is to provide a medical agent which specifically binds to FAPα, is effective in the treatment and diagnosis of tumors or cancers expressing FAPα, for example, in the treatment and diagnosis of solid...
|
|
WO/2023/154302A1 |
The invention provides macromolecule-supported compounds of Formula I comprising a macromolecule linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine de...
|
|
WO/2023/154307A1 |
The invention provides immunoconjugates of Formula. (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermedi...
|
|
WO/2023/143374A1 |
The present invention relates to a ligand, a method for preparing same, and a use thereof. The ligand has a structure represented by formula (I) or formula (II), wherein R1, R2, R3, and R4 are all linear structures with a glycosyl group ...
|
|
WO/2023/141693A1 |
The present disclosure relates to synthetic glycolipids of the formula (I): wherein • A represents (CH2)n with n being an integer from 2 to 10 or CH2-CH2-[O-CH2-CH2]m with m being an integer from 1 to 5; • B represents NR3 or OCH2, w...
|
|
WO/2023/141692A1 |
The present disclosure relates to synthetic glycolipids of the formula (I) wherein - A represents (CH2)n with n being an integer from 2 to 10 or CH2-CH2-[O-CH2-CH2]m with m being an integer from 1 to 5; - B represents NR3 or OCH2, with R...
|
|
WO/2023/144815A1 |
Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treat...
|
|
WO/2023/138664A1 |
The present invention is suitable for the technical field of nucleic acid drug delivery; specifically provided are a nucleic acid delivery compound, a liver-targeting nucleic acid ligand and the use thereof. Provided in the present inven...
|
|
WO/2023/138099A1 |
The present invention relates to a preparation method for miglitol. Specifically, the method of the present invention comprises: using a compound represented by formula VI as a raw material, subjecting the raw material to sulfonylation a...
|
|
WO/2023/135135A1 |
The present invention relates to new hyaluronic acid derivatives conjugated with molecules of natural origin endowed with anti-inflammatory and/or antioxidant properties and processes for manufacturing the same. The covalent link of thes...
|
|
WO/2023/131849A1 |
A composition comprising a mixture of two or more stereoisomers of a synthetic charged isoprenoid glycolipid of Formula (I), or a pharmaceutically acceptable salt thereof, in which n is 0 or 1, R and R' are independently hydrogen or hydr...
|
|
WO/2023/129737A1 |
Described herein are glycan compounds and particles comprising glycan compounds. The compounds and particles described herein are useful in methods of treating immune and inflammatory-related diseases. or a pharmaceutically acceptable sa...
|
|
WO/2023/120292A1 |
Provided is a method for producing a sulfonamide derivative, the method being characterized by including a step of causing a compound having a nitro group to react with a compound having a thiol group under light irradiation, and forming...
|
|
WO/2023/116301A1 |
The present invention relates to a method for preparing a liquid maltitol and a liquid polyol by using a maltitol chromatographic raffinate, comprising the following steps: hydrogenating a pretreated maltitol chromatographic raffinate to...
|
|
WO/2023/118500A1 |
Described herein are novel glycolipid surface-active compositions, products of, and methods of making the same.
|
|
WO/2023/121483A1 |
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator...
|
|
WO/2023/115054A1 |
This application relates to methods of inhibiting the growth of human pathogenic bacteria in or on a plant by treating the seeds of the plant with an aqueous solution containing one or more ascarosides. The application also provides a me...
|
|
WO/2023/114781A1 |
Dust poses a significant threat to human and environmental health. In 2015, an estimated 4.2 million deaths, as well as numerous health issues, were attributed to dust. Unlike other major contaminant transport pathways (e.g., water, soil...
|
|
WO/2023/114778A1 |
The present invention is directed to polymers comprising glycolipids and methods for producing and using the same. In particular, the polymers of the invention comprise a polymer backbone and a plurality of glycolipid side chains. The gl...
|
|
WO/2023/114746A1 |
Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide va...
|
|
WO/2023/102665A1 |
Describe herein are methods and products for increasing the secretion of extracellular vesicles (EVs) from a cell via ganglioside treatment. Such increased secretion may be used for example for increasing the removal of misfolded protein...
|
|
WO/2023/102658A1 |
Disclosed are novel glycosylated mescaline derivative compounds that exhibit selective binding to the HT1A receptor over HT2A receptor and pharmaceutical and recreational drug formulations containing the same. The compounds may be produc...
|
|
WO/2023/102659A1 |
Disclosed are novel mescaline derivative compounds, notably glycosylated isopropylamine derivatives of mescaline, and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting an iso...
|
|
WO/2023/099478A1 |
The present invention relates to a novel and efficient method for the production of sphingolipids via the N-acylation of lysosphingolipids. The method comprises the use of 1,3,5-triazine-based acylating agents, and is especially suitable...
|
|
WO/2023/099741A1 |
The present application relates to adjuvants and adjuvant-antigen conjugate vaccines based on a triterpene glycoside saponin scaffold incorporating an oxime group at position C4 of the triterpene domain and pharmaceutical compositions th...
|
|
WO/2023/099813A1 |
The disclosure relates to a method for producing anionic saccharides by reacting saccharide with a compound having a conjugated electron withdrawing group via oxa-Michael addition reaction for producing a derivatized saccharide followed ...
|
|
WO/2023/101389A1 |
The present invention relates to a method for producing a disaccharide using beta-glucosidase and a cofactor thereof and a composition for inducing the enzyme production of a strain of the genus Trichoderma, the composition comprising th...
|
